Abstract:Abstract Chronic pain affects one in five of the general population and is the third most important cause of disability-adjusted life-years globally. Unfortunately, treatment remains inadequate due to poor efficacy and tolerability. There has been a failure in translating promising preclinical drug targets into clinic use. This reflects challenges across the whole drug development pathway, from preclinical models to trial design. Nociceptors remain an attractive therapeutic target: their sensitization makes an important contribution to many chronic pain states, they are located outside the blood–brain barrier, and they are relatively specific. The past decade has seen significant advances in the techniques available to study human nociceptors, including: the use of corneal confocal microscopy and biopsy samples to observe nociceptor morphology, the culture of human nociceptors (either from surgical or post-mortem tissue or using human induced pluripotent stem cell derived nociceptors), the application of high throughput technologies such as transcriptomics, the in vitro and in vivo electrophysiological characterization through microneurography, and the correlation with pain percepts provided by quantitative sensory testing. Genome editing in human induced pluripotent stem cell-derived nociceptors enables the interrogation of the causal role of genes in the regulation of nociceptor function. Both human and rodent nociceptors are more heterogeneous at a molecular level than previously appreciated, and while we find that there are broad similarities between human and rodent nociceptors there are also important differences involving ion channel function, expression, and cellular excitability. These technological advances have emphasized the maladaptive plastic changes occurring in human nociceptors following injury that contribute to chronic pain. Studying human nociceptors has revealed new therapeutic targets for the suppression of chronic pain and enhanced repair. Cellular models of human nociceptors have enabled the screening of small molecule and gene therapy approaches on nociceptor function, and in some cases have enabled correlation with clinical outcomes. Undoubtedly, challenges remain. Many of these techniques are difficult to implement at scale, current induced pluripotent stem cell differentiation protocols do not generate the full diversity of nociceptor populations, and we still have a relatively poor understanding of inter-individual variation in nociceptors due to factors such as age, sex, or ethnicity. We hope our ability to directly investigate human nociceptors will not only aid our understanding of the fundamental neurobiology underlying acute and chronic pain but also help bridge the translational gap.

The genetic mediation of individual differences in sensitivity to pain and its inhibition

GENES CONTRIBUTING TO PAIN SENSITIVITY IN THE NORMAL POPULATION: AN EXOME SEQUENCING STUDY

Molecular Genetics of Variability in Human Pain

From mouse to humans: discovery of the CACNG2 pain susceptibility gene

Genetic contributions to pain: a review of findings in humans

Genetic architecture of human pain perception

Genetic variability of pain perception and treatment—clinical pharmacological implications

Genetics of pain, opioids, and opioid responsiveness

Systems genetics analysis reveals the common genetic basis for pain sensitivity and cognitive function

Genomic and transcriptomic profiles influence on brain morphology and their interactions with pain sensitivity individual differences

Epigenetics and Pain: New Insights to an Old Problem

Bridging the genetic gulf: a deep dive into neurotransmission, pharmacogenomics, and genetic variations for optimal pain management

Genetic and epigenetic of pain perception

MeCP2 Mediates Transgenerational Transmission of Chronic Pain

Is the Experience of Thermal Pain Genetics Dependent?

Systems genetic and pharmacological analysis identifies candidate genes underlying mechanosensation in the von Frey test

Studying human nociceptors: from fundamentals to clinic

Shared Genetic Regulatory Networks Contribute to Neuropathic and Inflammatory Pain: Multi-Omics Systems Analysis

Heritability of nociception. III. Genetic relationships among commonly used assays of nociception and hypersensitivity

Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling

Differential Methylation of the Trpa1 Promoter in Pain Sensitivity